WashU's PEP-CMV Peptide Vaccine Was Well Tolerated in Its First 36 Children and Young Adults With Aggressive Brain Tumors
In a Society for Neuro-Oncology abstract, Washington University researchers reported early safety data from a Phase 2 trial of PEP-CMV, a peptide vaccine aimed at the cytomegalovirus protein pp65, which these tumors carry but nearby normal brain does not. Thirty-six of a planned 106 patients aged 3 to 39 with recurrent medulloblastoma, newly diagnosed high-grade glioma, or diffuse intrinsic pontine glioma have received at least one dose. Grade 3 or 4 events possibly related to treatment included low blood counts, a seizure, and two cases of cytokine release syndrome. The authors called the vaccine well tolerated; efficacy results are not yet reported.